Clinical trials: Locally Advanced Head and Neck Carcinoma
Nasopharyngeal Carcinoma
GNT Induction Treatment in Locally Advanced NPC
The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal…
- Trial name
- NCT06026878
- Testing
- gemcitabine,nimotuzumab, toripalimab, gemcitabine, cisplatin
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Air Force Military Medical University, China
Esophageal Squamous Cell Carcinoma
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% unresectable…
- Trial name
- AdvanTIG-203 (NCT04732494)
- Testing
- Tislelizumab, Ociperlimab
- Where
- 86 sites in China, France and 4 more
- Volunteers
- 125 people
- Sponsor
- BeiGene
Squamous Cell Esophageal Carcinoma, Esophageal Cancer
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
The primary objective is to compare PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery, in terms of the overall survival time (OS) in patients…
- Conditions
- Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer
- Trial name
- NCT05357846
- Testing
- Sintilimab, Preoperative radiotherapy, Paclitaxel
- Where
- China
- Volunteers
- 422 people
- Sponsor
- Sun Yat-sen University
Salivary Gland Cancer, Adenoid Cystic Carcinoma
PSMA-PET Imaging for Advanced ACC/SDC
Diagnostic study which evaluates the level of PSMA expression in patients with locally advanced, recurrent and/or metastatic ACC/SDC of ≥18 years old with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are…
- Conditions
- Salivary Gland Cancer, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma
- Trial name
- NCT03319641
- Testing
- PSMA-PET/CT scan
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Radboud University Medical Center
Head and Neck Cancer
Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck
To evaluate the efficacy of first line oxaliplatin in combination with 5-fluorouracil (5-FU) in patients with advanced inoperable or metastatic head and neck cancer and to investigate the safety profile of this regimen in the…
- Trial name
- NCT00611754
- Testing
- Oxaliplatin, 5-FU
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Sanofi
Esophagus Cancer
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
Prediction for pCR After Neoadjuvant Immunotherapy Combined With Chemotherapy Using Single-Cell RNA Sequencing in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
- Trial name
- NCT05807542
- Testing
- Tislelizumab, Paclitaxel-albumin, Carboplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
Squamous Cell Carcinoma of the Head and Neck
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
A single-arm, single-center clinical trial evaluating efficacy (Phase #)
- Trial name
- NCT07550972
- Testing
- A single-arm, single-center clinical trial evaluating efficacy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Provincial People's Hospital
Head and Neck Cancer
Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, S-1, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00625937
- Testing
- cisplatin, docetaxel, tegafur-gimeracil-oteracil potassium
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Yonsei University
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
This phase I trial studies the best dose of sonidegib when given together with pembrolizumab and to see how well they work in treating patients with solid tumor that has spread to other places in the body (advanced).
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04007744
- Testing
- Pembrolizumab, Sonidegib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Cancer
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
The purpose of this study is to determine if the addition of a unique targeted agent called Cetuximab (also known as "C225" and "Erbitux") can increase the effectiveness of standard treatment with chemotherapy and radiation.
- Trial name
- NCT00226239
- Testing
- Docetaxel, Cisplatin, Cetuximab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pittsburgh
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APT-CUBE (NCT05473156)
- Testing
- AP203
- Where
- Taiwan
- Volunteers
- 168 people
- Sponsor
- AP Biosciences Inc.
Esophageal Squamous Cell Carcinoma
Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
Advanced esophageal squamous cell carcinoma patients who have failed first-line PD-1 inhibitor combined with chemotherapy lack a standard treatment option.
- Trial name
- NCT05990231
- Testing
- Cadonilimab combined Anlotinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Carcinoma
The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC）
The prognosis and safety of patients with locally advanced esophageal squamous cell carcinoma were compared with different neoadjuvant therapy modes in multi-cancer centers in China
- Trial name
- NEO-EC (NCT06828718)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Hebei Medical University Fourth Hospital
Locally Advanced Esophageal Squamous Cell Carcinoma
Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
This study evaluated the effectiveness and safety of sintilimab combined with cCRT in patients with locally advanced ESCC.
- Trial name
- NCT04602013
- Testing
- Sintilimab, Chemotherapy, Radiation Therapy
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
This is a Phase 2, multi-cohort study to investigate safety, PK, and preliminary anti-tumor activity of the monoclonal antibody BGB A317 in combination with standard chemotherapy as first-line treatment.
- Trial name
- NCT03469557
- Testing
- Tislelizumab, Cisplatin, 5-FU
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- BeiGene
Squamous Cell Carcinoma of Head and Neck
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
This is a Phase I dose-escalation study of sEphB4-HSA in combination with chemotherapy, cetuximab and radiotherapy (RT). The purpose is to estimate the maximum tolerated dose (MTD) that can be administered concurrently with…
- Trial name
- NCT04091867
- Testing
- sEphB4-HSA with chemotherapy, Cetuximab, Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
Head and Neck Neoplasms
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
To evaluate the rate of clinical complete response 6-8 weeks after treatment with docetaxel plus cisplatin and 5-fluorouracil followed by chemoradiotherapy and after chemoradiotherapy alone in patients with locally advanced…
- Trial name
- NCT00357149
- Testing
- Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy, Concomitant cisplatin, 5-FU and radiotherapy
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- Sanofi
Oral Cancer, VEGFR2 Inhibitor
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
In patients with locally advanced oral squamous cell carcinoma (OSCC), due to the large tumor burden and neck lymph node metastasis, comprehensive treatment is recommended, including surgery, radiotherapy, chemotherapy and…
- Conditions
- Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor, Inductive Therapy
- Trial name
- NCT04393506
- Testing
- Camrelizumab, Apatinib, Radical surgery
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Esophageal Cancer, Adenocarcinoma
A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer
The primary objective of this study is to assess the efficacy of nimotuzumab in combination with chemotherapy and radiotherapy for the treatment of locally advanced esophageal cancer, comparing it to that of the conventional…
- Trial name
- NICE (NCT01249352)
- Testing
- Nimotuzumab, Cisplatin, Fluorouracil
- Where
- 19 sites in Brazil
- Volunteers
- 104 people
- Sponsor
- Eurofarma Laboratorios S.A.
Locally Advanced Head and Neck Cancer
Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer
To confirm the feasibility of studying Xtampza ER during radiotherapy (RT) for LAHNC as part of a prospective clinical trial.
- Trial name
- RAD 1702 (NCT03317730)
- Testing
- Xtampza ER
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham